Milan

• A Phase 2b Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn’s Disease Recruiting
  2023-506704-14-00 4 2024-09-04 Moderately to Severely Active Crohn's Disease
• Pembrolizumab With or Without Maintenance MK‑2870 in Metastatic Squamous NSCLC Recruiting
  2023-510128-66-00 5 2024-09-02 Participants with treatment-naïve metastatic squamous Non-small Cell L
• First-in-human study of 225Ac-PSMA-Trillium (BAY 3563254) in participants with advanced metastatic castration-resistant prostate cancer (mCR … Recruiting
  2023-507486-26-00 1 2024-08-20 Advanced metastatic castration-resistant prostate cancer with prostate
• Phase 1/2a study of ATX-01 in participants with DM1 Recruiting
  2023-505363-37-00 1 2024-08-12 Myotonic dystrophy type 1 (DM1)
• First-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer Recruiting
  2023-508435-31-00 1 2024-08-09 Advanced Solid Tumors, Advanced Breast Cancer
• A randomized trial of multi-factorial primary prevention in high risk subjects candidate to a lung cancer early detection CT program Recruiting
  2024-513660-26-00 4 2024-08-06 Subjects at high risk of inflammatory state and mortality from lung ca
• Preventing caRdiovascular collapsE with VasoprEssors duriNg Tracheal IntubatiON: The PREVENTION Randomized Controlled Trial (PREVENTION tria … Recruiting
  2023-503895-25-00 5 2024-08-01 criticall illness
• A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro … Recruiting
  2023-508005-24-00 5 2024-08-01 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• A clinical study of MK-2870 alone or with other treatments to treat gastrointestinal cancers (MK-9999-02A) Recruiting
  2023-508703-21-00 9 2024-08-01 Colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), bili
• COMPARE STEMI ONE- Comparison Of reduced DAPT followed by P2Y12 inhibitor Monotherapy with Prasugrel vs stAndard Regimen in STEMI patients t … Recruiting
  2024-515883-30-00 6 2024-08-01 St-Elevated Myocardial Infartion
• Trial to assess the safety and efficacy of high dose pulse intravenous corticosteroid therapy to treat patients with complicated/fulminant a … Recruiting
  2023-504169-22-02 5 2024-07-31 Severe cardiac inflammation
• A study to test the effects and safety of riliprubart in people with chronic inflammatory demyelinating polyneuropathy (CIDP) for which the … Recruiting
  2023-506503-26-00 5 2024-07-31 Polyneuropathy, Inflammatory Demyelinating, Chronic
• A Study to Evaluate Whether Healing all Bowel Wall Layers is a Superior Treatment Target in Patients with Active Crohn’s Disease (CD). Recruiting
  2023-509096-16-00 6 2024-07-31 Moderately to Severely Active Crohn’s Disease
• A Phase 1 Study of JNJ-88549968, a T-cell Redirecting Antibody, for CALR-mutated Myeloproliferative Neoplasms Recruiting
  2023-505584-36-00 1 2024-07-30 CALR-mutated Myeloproliferative Neoplasms
• SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa … Recruiting
  2023-508260-30-01 5 2024-07-30 Patients with poor prognostic OVARian cancers based on the tumor prima
• A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alt … Recruiting
  2023-507684-19-00 5 2024-07-24 FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer
• A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on … Recruiting
  2022-502135-19-00 4 2024-07-18 Calcific Aortic Valve Stenosis
• Study of RMC-6291 and RMC-6236 With Other Anti-Cancer Agents in Patients With RAS G12C-Mutated NSCLC - Subprotocol A Recruiting
  2023-509571-16-00 3 2024-07-17 Lung Cancer
• A study of RMC-6236 in combination with pembrolizumab in participants with nonsmall cell lung cancer with certain mutations -Subprotocol B Recruiting
  2023-509572-42-00 3 2024-07-17 Lung Cancer
• A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate … Recruiting
  2024-511309-47-00 4 2024-07-17 moderate thrombocytopenia
• A clinical study of MK-2870 and chemotherapy to treat lung cancer (MK-2870-009) Recruiting
  2023-504910-31-00 5 2024-07-15 Non-small Cell Lung Cancer (NSCLC)
• Phase 2 Study of HER3-DXd in Locally Advanced or Metastatic Solid Tumors Recruiting
  2023-507641-29-00 4 2024-07-15 Locally Advanced or Metastatic Solid Tumors
• Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting
  2023-508162-15-00 5 2024-07-12 Chronic HF and comorbid impairment of kidney function who had a recent
• Surgical treatment with or without apalutamide in subjects with high risk prostate cancer who are candidates for radical prostatectomy and s … Recruiting
  2024-515049-41-00 4 2024-07-12 metastatic prostate cancer

Showing 913–936 of 2,361 trials